A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Connect Biopharm LLC324 enrolled

Overview

This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.

A total of 324 healthy subjects are planned to be enrolled and randomized into 3 groups at a ratio of 1:1:1, with 108 subjects in each group. They will receive 2 doses of the test drug T1 (CBP-201 injection (pre-filled syringe, 150 mg/1 mL)), 1 dose of the test drug T2 (CBP-201 injection (pre-filled syringe, 300 mg/2 mL)), and 2 doses of the reference drug R (CBP-201 injection (vial, 150 mg/1 mL)), respectively. The study consists of a screening period (Day-28 to Day-2), a baseline period (Day-1), an administration and observation period (Day1 to Day6), and a follow-up period (Day7 to Day57).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

324

Conditions

Healthy Adult Subjects

Interventions

Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)BIOLOGICAL

subcutaneous injection of 2 doses on Day 1

Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)BIOLOGICAL

subcutaneous injection of 1 dose on Day 1

Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)BIOLOGICAL

subcutaneous injection of 2 doses on Day 1

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects who are to read, understand, and sign the ICF. 2. Healthy adult male or female subjects aged 18-45 years (inclusive) at screening, with each sex accounting for at least one-third of the overall sample size. 3. Body mass index (BMI) is between 19 and 28 kg/m2 (inclusive). Male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg. 4. Subjects with partners must agree to take medically accepted effective contraceptive measures (including physical contraception, surgery, abstinence, etc) from signing of the ICF until 90 days after administration. 5. The results of vital sign assessment, physical examination, clinical laboratory tests (hematology, urinalysis, biochemistry, coagulation) and 12-lead ECG at screening or baseline are normal or abnormal but not clinically significant. 6. Subjects who are able to communicate well with the clinical staff and complete the study according to the protocol. Exclusion Criteria: 1. Subjects who have diseases or conditions with abnormal clinical manifestations, including but not limited to renal, cardiac, hematological, bronchial, pulmonary, vascular, gastrointestinal, allergic, neurological, endocrine and metabolic diseases (diabetes mellitus, thyroid disorder, and adrenal disorder), skeletal disease and immunodeficiency, cancer, and hepatitis, or cirrhosis. 2. Subjects with allergic diseases (such as allergic rhinitis, allergic asthma) at screening, a history of systemic anaphylaxis, or who may be allergic to any component of the test drugs or similar drugs as determined by the investigator. 3. Subjects who have donated blood or have had substantial loss of blood (\> 400 mL) within 3 months before administration. 4. Subjects who have been vaccinated with live (attenuated) vaccines within 3 months before administration. 5. Subjects who have participated in clinical studies of other drugs within 3 months before administration. 6. Subjects who have taken any prescription drugs, over-the-counter drugs, vitamin products, Chinese patent medicines, and Chinese herbal medicines within 1 month before administration. 7. Subjects who have been diagnosed with clinically significant diseases or have undergone major surgical procedures within 1 month before administration, or who are scheduled to undergo major surgery during the study. 8. Female subjects who test positive for pregnancy at screening or baseline or who are lactating. 9. Subjects who smoke more than 5 cigarettes or equivalent per day within 3 months before administration. 10. Subjects who have a history of drug abuse within the last 5 years, who have used narcotics within 3 months before administration, or who test positive in urine drug screening at the screening/baseline visit. 11. Subjects who have a history of regular alcohol consumption, which is defined as consumption of more than 7 units of alcohol per week for females or more than 14 units of alcohol per week for males (1 unit of alcohol equals 360 mL of beer, 45 mL of 40% liquor, or 150 mL of wine) within 3 months before administration, who take any alcohol-containing product within 48 h before administration, or who test positive in blood alcohol tests at the screening/ baseline visit. 12. Subjects with known symptoms of dermatitis or skin abnormalities at and around the site of administration. 13. Subjects who test positive for treponema pallidum antibody (TP-Ab), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (HCV-Ab), and human immunodeficiency virus antibody (HIV-Ab). 14. Patients with active tuberculosis, latent tuberculosis, or nontuberculous mycobacterial infection at screening; Notes: * Unless treatment records clearly documented by a specialist demonstrate that the patients have been adequately treated and may begin treatment with biological product (based on the medical judgment by the investigator and/or infectious disease specialist); * If needed, T-spot tests may be used to assist diagnosis of suspected tuberculosis. 15. Subjects with white blood cell count and neutrophil count below the lower limit of normal. 16. Female subjects with hemoglobin values less than 110 g/L or male subjects less than 120 g/L. 17. Subjects who cannot tolerate venous blood sampling, or who have a history of acupuncture syncope or hemophobia. 18. Subjects who still need or plan to engage in strenuous physical activity or exercise during the study. 19. Any other conditions that the investigator determines may affect the subject's provision of informed consent or compliance with the study protocol, or that the investigator deems unsuitable for participation in this study, or the subjects' participation in the study may affect the study results or their own safety.

Locations (1)

The Second Hospital of Anhui Medical University

Hefei, Anhui, China

Outcomes

Primary Outcomes

Cmax: Maximum concentration

Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

AUC0-t: Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T

Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

AUC0-inf: Area under the plasma concentration-time curve from the start of administration to infinity

Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Secondary Outcomes

Maximum concentration (Cmax)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T (AUC0-t)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Area under the plasma concentration-time curve from the start of administration to infinity (AUC0-inf)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Time to peak (Tmax)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Elimination half-life (t1/2)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Apparent clearance (CL/F)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Apparent volume of distribution (Vz/F)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Terminal elimination phase rate constant (λz)

Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Adverse events (AEs)

All adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) (the latest version).

Time frame: Up to 57 days post dosing

Injection site reactions

The injection site will be examined and the results will be judged by the investigator.

Time frame: Day1, Day2, Day3, Day4, Day6, Day8, Day15, Day22, Day29, Day57

Blood Pressure (systolic and diastolic blood pressures)

The results as well as their changes from baseline will be statistically summarized by dose group and visit.

Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

Pulse

The results as well as their changes from baseline will be statistically summarized by dose group and visit.

Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

Body Temperature (ear temperature)

The results as well as their changes from baseline will be statistically summarized by dose group and visit.

Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

Respiratory Rate

The results as well as their changes from baseline will be statistically summarized by dose group and visit.

Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

Physical examination

Physical examination items include: skin (including observation of the planned injection site (abdomen) and surrounding skin during the screening period and at baseline), lymph nodes, head, eyes, neck, chest, abdomen, spine/extremities, and nervous system. The results of physical examination will be evaluated by investigator's observation.

Time frame: pre-dose, Day6, Day15, Day29, Day57

12-lead electrocardiogram (ECG)

ECG variables include ventricular heart rate, PR interval, QRS interval, QT interval, and QTcF interval.

Time frame: pre-dose, Day1, Day2, Day4, Day6, Day10, Day15, Day22, Day29, Day36, Day43, Day57

Clinical laboratory test: Hematology - Hemoglobin (Hgb)

The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.